Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
34
IDXG Quote, Financials, Valuation and Earnings
Last price:
$1.79
Seasonality move
:
20.62%
Day range:
$1.79 - $1.79
52-week range:
$0.44 - $1.91
Dividend yield:
0%
P/E ratio:
6.64x
P/S ratio:
0.68x
P/B ratio:
--
Volume:
101
Avg. volume:
8.3K
1-year change:
55.22%
Market cap:
$49.4M
Revenue:
$46.9M
EPS (TTM):
$0.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
-- | -- | -- | -- | -- |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
FUNI
Hypha Labs, Inc.
|
-- | -- | -- | -- | -- |
|
TMO
Thermo Fisher Scientific, Inc.
|
$11.9B | $6.45 | 4.93% | 33.06% | $666.46 |
|
VCYT
Veracyte, Inc.
|
$135.8M | $0.41 | 13.92% | 278.73% | $48.60 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
$1.79 | -- | $49.4M | 6.64x | $0.00 | 0% | 0.68x |
|
FONR
FONAR Corp.
|
$18.53 | -- | $116.8M | 16.46x | $0.00 | 0% | 1.11x |
|
FUNI
Hypha Labs, Inc.
|
$0.03 | -- | $5M | 4.88x | $0.00 | 0% | 1.16x |
|
TMO
Thermo Fisher Scientific, Inc.
|
$512.69 | $666.46 | $192.6B | 28.90x | $0.43 | 0.34% | 4.35x |
|
VCYT
Veracyte, Inc.
|
$36.27 | $48.60 | $2.9B | 44.17x | $0.00 | 0% | 5.60x |
|
XWEL
XWELL, Inc.
|
$1.35 | -- | $7.8M | -- | $0.00 | 0% | 0.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
115.19% | 2.523 | 56.7% | 1.24x |
|
FONR
FONAR Corp.
|
18.36% | 1.073 | 38.72% | 11.15x |
|
FUNI
Hypha Labs, Inc.
|
-290.87% | 1.956 | 26.69% | 0.03x |
|
TMO
Thermo Fisher Scientific, Inc.
|
42.44% | 0.857 | 18.08% | 1.37x |
|
VCYT
Veracyte, Inc.
|
2.94% | 0.659 | 1.19% | 7.63x |
|
XWEL
XWELL, Inc.
|
278.04% | -5.207 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
$5.4M | $1.1M | 283.22% | -- | 13.08% | $1.8M |
|
FONR
FONAR Corp.
|
$9.7M | $3M | 4.84% | 6.02% | 11.74% | -$167K |
|
FUNI
Hypha Labs, Inc.
|
-$11.7K | -$475K | -28992.29% | -- | -- | -$150.2K |
|
TMO
Thermo Fisher Scientific, Inc.
|
$4.6B | $2.3B | 7.8% | 13.23% | 18.85% | $3B |
|
VCYT
Veracyte, Inc.
|
$101.4M | $25.9M | 5.19% | 5.39% | 18.45% | $48.8M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
Interpace Biosciences, Inc. vs. Competitors
-
Which has Higher Returns IDXG or FONR?
FONAR Corp. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of 9.94%. Interpace Biosciences, Inc.'s return on equity of -- beat FONAR Corp.'s return on equity of 6.02%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M FONRFONAR Corp.37.95% $0.31 $202.7M -
What do Analysts Say About IDXG or FONR?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 516.25%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Interpace Biosciences, Inc. has higher upside potential than FONAR Corp., analysts believe Interpace Biosciences, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 FONRFONAR Corp.0 0 0 -
Is IDXG or FONR More Risky?
Interpace Biosciences, Inc. has a beta of 1.170, which suggesting that the stock is 16.957% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 0.990, suggesting its less volatile than the S&P 500 by 0.972%.
-
Which is a Better Dividend Stock IDXG or FONR?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or FONR?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are smaller than FONAR Corp. quarterly revenues of $25.5M. Interpace Biosciences, Inc.'s net income of $1M is lower than FONAR Corp.'s net income of $2.5M. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.64x while FONAR Corp.'s PE ratio is 16.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.68x versus 1.11x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.68x 6.64x $8.8M $1M FONRFONAR Corp.1.11x 16.46x $25.5M $2.5M
-
Which has Higher Returns IDXG or FUNI?
Hypha Labs, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of --. Interpace Biosciences, Inc.'s return on equity of -- beat Hypha Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M FUNIHypha Labs, Inc.-- -$0.00 -$601.6K -
What do Analysts Say About IDXG or FUNI?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 516.25%. On the other hand Hypha Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Interpace Biosciences, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Hypha Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 FUNIHypha Labs, Inc.0 0 0 -
Is IDXG or FUNI More Risky?
Interpace Biosciences, Inc. has a beta of 1.170, which suggesting that the stock is 16.957% more volatile than S&P 500. In comparison Hypha Labs, Inc. has a beta of 1.235, suggesting its more volatile than the S&P 500 by 23.534%.
-
Which is a Better Dividend Stock IDXG or FUNI?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hypha Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. Hypha Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or FUNI?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are larger than Hypha Labs, Inc. quarterly revenues of --. Interpace Biosciences, Inc.'s net income of $1M is higher than Hypha Labs, Inc.'s net income of -$521.6K. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.64x while Hypha Labs, Inc.'s PE ratio is 4.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.68x versus 1.16x for Hypha Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.68x 6.64x $8.8M $1M FUNIHypha Labs, Inc.1.16x 4.88x -- -$521.6K
-
Which has Higher Returns IDXG or TMO?
Thermo Fisher Scientific, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of 16.21%. Interpace Biosciences, Inc.'s return on equity of -- beat Thermo Fisher Scientific, Inc.'s return on equity of 13.23%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M TMOThermo Fisher Scientific, Inc.37.95% $5.21 $92.9B -
What do Analysts Say About IDXG or TMO?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 516.25%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $666.46 which suggests that it could grow by 29.99%. Given that Interpace Biosciences, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Thermo Fisher Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 TMOThermo Fisher Scientific, Inc.18 4 0 -
Is IDXG or TMO More Risky?
Interpace Biosciences, Inc. has a beta of 1.170, which suggesting that the stock is 16.957% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.962, suggesting its less volatile than the S&P 500 by 3.778%.
-
Which is a Better Dividend Stock IDXG or TMO?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.34% to investors and pays a quarterly dividend of $0.43 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.7% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IDXG or TMO?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $12.2B. Interpace Biosciences, Inc.'s net income of $1M is lower than Thermo Fisher Scientific, Inc.'s net income of $2B. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.64x while Thermo Fisher Scientific, Inc.'s PE ratio is 28.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.68x versus 4.35x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.68x 6.64x $8.8M $1M TMOThermo Fisher Scientific, Inc.4.35x 28.90x $12.2B $2B
-
Which has Higher Returns IDXG or VCYT?
Veracyte, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of 29.26%. Interpace Biosciences, Inc.'s return on equity of -- beat Veracyte, Inc.'s return on equity of 5.39%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M VCYTVeracyte, Inc.72.07% $0.51 $1.3B -
What do Analysts Say About IDXG or VCYT?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 516.25%. On the other hand Veracyte, Inc. has an analysts' consensus of $48.60 which suggests that it could grow by 34%. Given that Interpace Biosciences, Inc. has higher upside potential than Veracyte, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 VCYTVeracyte, Inc.8 2 1 -
Is IDXG or VCYT More Risky?
Interpace Biosciences, Inc. has a beta of 1.170, which suggesting that the stock is 16.957% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.915, suggesting its more volatile than the S&P 500 by 91.504%.
-
Which is a Better Dividend Stock IDXG or VCYT?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or VCYT?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are smaller than Veracyte, Inc. quarterly revenues of $140.6M. Interpace Biosciences, Inc.'s net income of $1M is lower than Veracyte, Inc.'s net income of $41.1M. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.64x while Veracyte, Inc.'s PE ratio is 44.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.68x versus 5.60x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.68x 6.64x $8.8M $1M VCYTVeracyte, Inc.5.60x 44.17x $140.6M $41.1M
-
Which has Higher Returns IDXG or XWEL?
XWELL, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of -2.87%. Interpace Biosciences, Inc.'s return on equity of -- beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About IDXG or XWEL?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 516.25%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 418.52%. Given that Interpace Biosciences, Inc. has higher upside potential than XWELL, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than XWELL, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 XWELXWELL, Inc.0 0 0 -
Is IDXG or XWEL More Risky?
Interpace Biosciences, Inc. has a beta of 1.170, which suggesting that the stock is 16.957% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.449%.
-
Which is a Better Dividend Stock IDXG or XWEL?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or XWEL?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Interpace Biosciences, Inc.'s net income of $1M is higher than XWELL, Inc.'s net income of -$211K. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.64x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.68x versus 0.25x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.68x 6.64x $8.8M $1M XWELXWELL, Inc.0.25x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 5.4% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 8.3% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 7.49% over the past day.
